Boston Scientific (NYSE:BSX) announced today that it completed its previously announced acquisition of Nalu Medical.

At the recently concluded North American Neuromodulation Society annual meeting, Boston presented a total of 17 abstracts.

BCI® Therapy is being developed to restore thought-driven movement in people living with spinal cord injuries and other ...

Boston Scientific is recommended as a buy with a $109 target price, implying 14% upside, driven by robust demand and niche leadership. BSX outpaces market growth through focused M&A, strong execution ...

Boston Scientific continues to deliver robust growth, but valuation limits upside despite strong execution and leading positions in key medical device markets. BSX's growth drivers—Farapulse (PFA), ...

In the latest close session, Boston Scientific (BSX) was down 1.02% at $91.75. The stock's change was less than the S&P 500's daily gain of 0.21%. Elsewhere, the Dow saw an upswing of 1.35%, while the ...

Boston Scientific is one of those companies that most people never think about until they need it. Its products are not seen on drugstore shelves or marketed on television. Instead, they sit inside ...

Over the past several years, Boston Scientific BSX has pursued a series of acquisitions in support of its growth strategy, both strengthening its core businesses and expanding into high-growth ...

—–In an interview with MedPage Today, Dr. Kapoor, from the Department of Pain Management at Cleveland Clinic, discusses the role of implantation of a permanent neuromodulation device in management of ...